Home - Products - Others - Other Targets - α-Synuclein (45-54) (human) trifluoroacetate salt

α-Synuclein (45-54) (human) trifluoroacetate salt

CAS No. ———

α-Synuclein (45-54) (human) trifluoroacetate salt( ——— )

Catalog No. M40899 CAS No. ———

α-Synuclein (45-54) (human) trifluoroacetate salt

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    α-Synuclein (45-54) (human) trifluoroacetate salt
  • Note
    Research use only, not for human use.
  • Brief Description
    α-Synuclein (45-54) (human) trifluoroacetate salt
  • Description
    α-Synuclein (45-54) (human) trifluoroacetate salt
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    996.12
  • Molecular Formula
    C473H73N13O14
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • α-Conotoxin GI

    α-Conotoxin GI has high affinity for nAChR.α-Conotoxin GI is a short peptide toxin that can be isolated from the venom of Conus geographus.α-Conotoxin GI has the similar activity with neuromuscular blocking agent.

  • Runcaciguat

    Runcaciguat is a soluble guanylate cyclase stimulator. Runcaciguat combines with selective partial adenosine A1 receptor agonists and can be used in studies about cardiovascular and renal diseases.

  • BMS-P5 free base

    BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor.?BMS-P5 Blocks Formation of Neutrophil Extracellular Traps and Delays Progression of Multiple Myeloma.